Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 2:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 53 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Benralizumab Clear all
Completed No phase listed Observational

RANS. Study in Patients With Severe Eosinophilic Asthma and Nasal Polyps.

NCT05180357
View directory record Official record
Conditions
Severe Eosinophilic Asthma, Nasal Polyps
Interventions
FASENRA(benralizumab)
Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
8
States / cities
Centennial, Colorado • Denver, Colorado • Glendale, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Sep 2, 2026, 2:03 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)

NCT04191304
View directory record Official record
Conditions
Hypereosinophilic Syndrome
Interventions
Benralizumab, Placebo
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 130 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
8
States / cities
La Jolla, California • Atlanta, Georgia • Bethesda, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 2, 2026, 2:03 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess Functionality, Reliability, and Performance of a Pre-filled Syringe With Benralizumab Administered at Home

NCT02417961
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
12
States / cities
Fountain Valley, California • Walnut Creek, California • Celebration, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Sep 2, 2026, 2:03 AM EDT
Completed Phase 3 Interventional Results available

A Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus LABA

NCT02258542
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 75 Years
Enrollment
2,133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
100
States / cities
Andalusia, Alabama • Birmingham, Alabama • Scottsboro, Alabama + 80 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Sep 2, 2026, 2:03 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Benralizumab Added to High-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma

NCT01928771
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab, Placebo
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 75 Years
Enrollment
2,681 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
110
States / cities
Foley, Alabama • Huntsville, Alabama • Mobile, Alabama + 107 more
Source: ClinicalTrials.gov public record
Updated May 2, 2017 · Synced Sep 2, 2026, 2:03 AM EDT
Not yet recruiting Phase 4 Interventional

Fasenra: An Asthma Study

NCT07654842
View directory record Official record
Conditions
Eosinophilic Asthma, Severe Asthma, Severe Eosinophilic Asthma, Asthma
Interventions
Budesonide-albuterol, Benralizumab
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Skokie, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 2, 2026, 2:03 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Benralizumab in Adults and Adolescents Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting β2 Agonist

NCT01914757
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab, Placebo
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 75 Years
Enrollment
2,508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
81
States / cities
Andalusia, Alabama • Birmingham, Alabama • Flagstaff, Arizona + 78 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Sep 2, 2026, 2:03 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Efficacy and Safety of Benralizumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma

NCT03557307
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
598 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
23
States / cities
Flagstaff, Arizona • Los Angeles, California • Aurora, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Sep 2, 2026, 2:03 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess Functionality, Reliability, and Performance of a Single-Use Auto-Injector With Benralizumab Administered at Home

NCT02918071
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
14
States / cities
Northridge, California • Riverside, California • Westminster, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2018 · Synced Sep 2, 2026, 2:03 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety Study of the Use of Benralizumab for Patients With Moderate to Severe Atopic Dermatitis

NCT04605094
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Benralizumab, Placebo / Benralizumab
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 130 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
13
States / cities
Los Angeles, California • Newport Beach, California • Bridgeport, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Sep 2, 2026, 2:03 AM EDT
Terminated No phase listed Observational

Benralizumab Pregnancy Exposure Study

NCT03794999
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab-exposure, Exposure to other asthma medications
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Female only
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Sep 2, 2026, 2:03 AM EDT
Completed Phase 4 Interventional Results available

BURAN: Benralizumab on Airway Dynamics in Severe Eosinophilic Asthma Using Functional Respiratory Imaging

NCT05552508
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab
Combination Product
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
10
States / cities
Walnut Creek, California • Loxahatchee Groves, Florida • Plantation, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Sep 2, 2026, 2:03 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of Benralizumab in Patient With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID)

NCT04157335
View directory record Official record
Conditions
Nasal Polyposis, Eosinophilic Chronic Rhinosinusitis
Interventions
Benralizumab 30 mg, Matched placebo
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
15
States / cities
Huntington Beach, California • Grand Junction, Colorado • Gainesville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Sep 2, 2026, 2:03 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2a Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Adults With Asthma

NCT00783289
View directory record Official record
Conditions
Asthma
Interventions
Placebo, Benralizumab 25 mg, Benralizumab 100 mg, Benralizumab 200 mg
Other · Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
Encinitas, California • Los Angeles, California • Colorado Springs, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced Sep 2, 2026, 2:03 AM EDT
Completed Phase 3 Interventional Results available

A Safety Extension Study With Benralizumab for Asthmatic Adults on Inhaled Corticosteroid Plus Long-acting β2 Agonist

NCT02808819
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
52
States / cities
Scottsboro, Alabama • Glendale, Arizona • Phoenix, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Sep 2, 2026, 2:03 AM EDT
Completed Phase 2 Interventional Results available

Benralizumab Effect on Severe Chronic Rhinosinusitis With Eosinophilic Polyposis

NCT03450083
View directory record Official record
Conditions
Chronic Rhinosinusitis (Diagnosis), Nasal Polyps, Eosinophilia
Interventions
Benralizumab, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Sep 2, 2026, 2:03 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Benralizumab for Eosinophilic Gastritis (BEGS)

NCT03473977
View directory record Official record
Conditions
Eosinophilic Gastritis or Gastroenteritis
Interventions
Benralizumab, Placebo
Biological
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
12 Years to 60 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 2, 2022 · Synced Sep 2, 2026, 2:03 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.

NCT04157348
View directory record Official record
Conditions
Eosinophilic Granulomatous Vasculitis
Interventions
Benralizumab, Mepolizumab, Placebo to Mepolizumab, Placebo to Benralizumab
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
9
States / cities
Denver, Colorado • Ann Arbor, Michigan • Rochester, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 2, 2026, 2:03 AM EDT
Recruiting Phase 3 Interventional

Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment

NCT07444567
View directory record Official record
Conditions
Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilic Syndrome (HES)
Interventions
Benralizumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
6 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
8
States / cities
Aurora, Colorado • Bethesda, Maryland • Ann Arbor, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 2, 2026, 2:03 AM EDT
Active, not recruiting Phase 2 Interventional

Benralizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study

NCT03010436
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab
Drug
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 100 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 7, 2021 · Synced Sep 2, 2026, 2:03 AM EDT
Completed Phase 3 Interventional Results available

Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History

NCT02138916
View directory record Official record
Conditions
Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Interventions
Benralizumab Arm A, Benralizumab Arm B, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 85 Years
Enrollment
1,656 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
138
States / cities
Andalusia, Alabama • Birmingham, Alabama • Dothan, Alabama + 114 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Sep 2, 2026, 2:03 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Benralizumab in Patients With Eosinophilic Gastritis and/or Gastroenteritis (The HUDSON GI Study)

NCT05251909
View directory record Official record
Conditions
Eosinophilic Gastritis, Eosinophilic Gastroenteritis
Interventions
Benralizumab, Placebo
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 130 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
7
States / cities
Chicago, Illinois • Boston, Massachusetts • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2025 · Synced Sep 2, 2026, 2:03 AM EDT
Recruiting Phase 4 Interventional

Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping

NCT06385236
View directory record Official record
Conditions
Moderate to Severe Asthma
Interventions
Dupilumab, Benralizumab
Biological
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
Scottsdale, Arizona • La Jolla, California • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 18, 2024 · Synced Sep 2, 2026, 2:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability and Effects of MEDI-563 in Adults With Asthma

NCT00659659
View directory record Official record
Conditions
Asthma
Interventions
MEDI-563, Placebo Comp., Placebo
Drug · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
6
States / cities
Denver, Colorado • Pittsburgh, Pennsylvania • Galveston, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2012 · Synced Sep 2, 2026, 2:03 AM EDT